Lenalidomide after response for primary brain lymphoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial studies lenalidomide taken after your first treatment has worked for primary central nervous system lymphoma (PCNSL). It aims to help keep the lymphoma from coming back by testing lenalidomide as ongoing “maintenance” treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed primary central nervous system lymphoma (PCNSL) on biopsy/pathology
- Your first-line chemo/immunotherapy worked (you had a complete or partial response)
- Your health status is good enough for study treatment (ECOG score less than 3)
- Blood and liver/kidney numbers are within required safety ranges (including enough white blood cells/platelets and kidney function)
- If you can become pregnant: you must have negative pregnancy tests and use birth control rules (or commit to no heterosexual sex)
- If you are male: you must use a latex condom during sex with someone who could become pregnant, even if you had a vasectomy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether lenalidomide and rituximab can help keep primary CNS lymphoma from coming back after initial chemotherapy. It may be an option if you cannot do a transplant and you can take pills.
This trial studies whether lenalidomide maintenance (ongoing pill treatment after remission) can help prevent relapse in people with primary central nervous system lymphoma or primary eye lymphoma. It’s aimed at adults who already completed standard chemo and radiation and are now in a complete or partial response.
This Phase 1 trial tests adding two cancer medicines—lenalidomide and nivolumab—to the usual treatment for primary CNS diffuse large B-cell lymphoma (a type of lymphoma in the brain/spinal fluid). The goal is to see if the combination is safe and if it works better than the usual approach.
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, for people whose central nervous system lymphoma has come back. The goal is to see if this treatment can help shrink the cancer or slow its growth.
This trial tests whether a maintenance drug called obinutuzumab can help prevent relapse in people with primary central nervous system lymphoma (a rare lymphoma in the brain or spine) who have already responded to initial chemotherapy. It is for those who have achieved at least a partial or complete response to their first treatment.
Hear when a new Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.